Login to Your Account



Idenix raises $106.7M war chest for clinical trials, patent litigation

By Marie Powers
Staff Writer

Wednesday, January 29, 2014
Shares of Idenix Pharmaceuticals Inc. (NASDAQ:IDIX) climbed steadily on Tuesday after the company disclosed that it plans to sell 16.4 million shares of common stock at $6.50 apiece to entities managed by the Baupost Group LLC. The hedge fund increased its stake in Idenix from 27 percent to approximately 35 percent of outstanding shares.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription